USPTO serial 85213907
PALLIARE
Reviewed by CopyMark Law Group
Reg. 4188810Status 710
- Filing date
- Status date
- Registration date
- Aug 14, 2012
- Examiner
- MCCAULEY, BRENDAN D
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with PALLIARE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Dangan, Galway, IE
Dangan, Galway, IE
Dangan, Galway, IE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leigh Ann Lindquist
LEIGH ANN LINDQUIST SUGHRUE MION, PLLC2100 PENNSYLVANIA AVE NWWASHINGTON, DC 20037-3202UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical and veterinary delivery apparatus, equipment, instruments, devices and systems, namely, drug delivery agents in the form of tablets, powders, capsules, pills, caplets, liquid drops and sachets that provide controlled release of active ingredients for a wide variety of medicaments, pharmaceuticals, vaccines and drugs for delivery thereof intradermally, transdermally, subcutaneously or otherwise through the skin; transdermal patches for use in the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal and dermatological diseases and disorders, immune system related diseases and disorders, cancer, autoimmune diseases and disorders, diabetes, kidney diseases and disorders, ocular diseases and disorders, bacteria-based diseases and disorders, influenza, psychiatric diseases and disorders, voice disorders, digestive disorders, vulvovaginal disorders, congenital disorders, depression, eating disorders, anorexia, obesity, infectious diseases and bone diseases containing medicaments, pharmaceuticals, vaccines and drugs for delivery thereof intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needle devices, namely, active transdermal micro-needle drug delivery patches for use in the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal and dermatological diseases and disorders, immune system related diseases and disorders, cancer, autoimmune diseases and disorders, diabetes, kidney diseases and disorders, ocular diseases and disorders, bacteria-based diseases and disorders, influenza, psychiatric diseases and disorders, voice disorders, digestive disorders, vulvovaginal disorders, congenital disorders, depression, eating disorders, anorexia, obesity, infectious diseases and bone diseases containing medicaments, pharmaceuticals, vaccines and drugs intradermally, transdermally, subcutaneously or otherwise through the skin; cartridges sold pre-filled with medicaments, pharmaceuticals, vaccines and drugs for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal and dermatological diseases and disorders, immune system related diseases and disorders, cancer, autoimmune diseases and disorders, diabetes, kidney diseases and disorders, ocular diseases and disorders, bacteria-based diseases and disorders, influenza, psychiatric diseases and disorders, voice disorders, digestive disorders, vulvovaginal disorders, congenital disorders, depression, eating disorders, anorexia, obesity, infectious diseases and bone diseases used in medical and veterinary delivery apparatus, equipment, instruments, devices and systems; and cartridges sold pre-filled with medicaments, pharmaceuticals, vaccines and drugs for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal and dermatological diseases and disorders, immune system related diseases and disorders, cancer, autoimmune diseases and disorders, diabetes, kidney diseases and disorders, ocular diseases and disorders, bacteria-based diseases and disorders, influenza, psychiatric diseases and disorders, voice disorders, digestive disorders, vulvovaginal disorders, congenital disorders, depression, eating disorders, anorexia, obesity, infectious diseases and bone diseases used in micro-needle devices; preparations for use in dialysis, namely, pharmaceutical solutions used in dialysis | SECTION 8 - CANCELLED | — |
| 010 | Medical and veterinary apparatus, equipment, instruments and devices, namely, micro-needles for medical use; transdermal drug delivery patches sold without medication; medical and veterinary delivery apparatus, equipment, instruments, devices and systems, namely, drug delivery patches sold without medication, electronic-kinetic transdermal drug delivery control unit for the treatment of diseases for delivering medicaments, pharmaceuticals, vaccines and other substances intradermally, transdermally, subcutaneously or otherwise through the skin; medical and veterinary apparatus, equipment, instruments, devices and systems, namely, micro-needles for medical use, medical needles and introducers, drainage tubes for medical purposes and wound suction apparatus for withdrawing bodily substances intradermally, transdermally, subcutaneously or otherwise through the skin; drug delivery patches sold without medication for delivering medicaments, pharmaceuticals, vaccines and other substances intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needle devices, namely, active transdermal micro-needle drug delivery patches sold without medication for the treatment of diseases for delivering medicaments, pharmaceuticals, vaccines and other substances intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needle devices, namely, active transdermal micro-needle drug delivery patches sold without medication for the treatment of diseases for withdrawing bodily substances intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needles for delivering medicaments, pharmaceuticals, vaccines and other substances intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needles for withdrawing bodily substances intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needle pads, namely, transdermal micro-needle arrays for delivering medicaments, pharmaceuticals, vaccines and other substances intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needle elements, namely, needle-free injection systems, needle-based injection systems and injection instruments with needles for use in such micro-needle devices; cartridges sold empty specially designed for holding medicaments, pharmaceuticals, vaccines and drugs for use in medical and veterinary delivery apparatus, equipment, instruments, devices and systems; cartridges sold empty specially designed for holding medicaments, pharmaceuticals, vaccines and drugs used in micro-needle devices; needles for medical and veterinary purposes; diagnostic apparatus, equipment, instruments, devices and systems, namely, blood pressure monitors, hematology analyzers for medical diagnostic uses and haemostats for medical and veterinary purposes; dialysis machines for medical use | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 15, 2019 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Aug 14, 2017 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Aug 14, 2012 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 29, 2012 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 29, 2012 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 9, 2012 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 4, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 21, 2012 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 17, 2012 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 1, 2012 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 1, 2012 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 1, 2012 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 1, 2012 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 12, 2011 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 12, 2011 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 12, 2011 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 17, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 17, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 8, 2011 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 3, 2011 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2011 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2011 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 14, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 14, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 27, 2011 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 6, 2011 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 6, 2011 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 6, 2011 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 30, 2011 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 3, 2011 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Mar 3, 2011 | ALIE | ASSIGNED TO LIE | — |
| Feb 22, 2011 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jan 13, 2011 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 13, 2011 | NWAP | NEW APPLICATION ENTERED | — |